Glenn has 30 years of executive management and Board experience in rapid growth biotechnology companies. He has raised and managed over $100M in equity capital and collaborative R&D funding. Glenn has particular expertise and experience in the management of drug discovery and drug development programs together with a successful track record in negotiating and executing major commercial and corporate transactions including license agreements, mergers and acquisitions, and equity capital raisings. Past roles include: CEO and Managing Director of VGI Health Technology Limited (NSX:VTL), the Molecular Plant Breeding CRC and Molecular Plant Breeding Pty Ltd., and AgGenomics Pty Ltd. (a subsidiary of Genetic Technologies Limited, ASX:GTG). Glenn is a Fellow of the Australian Institute of Company Directors.
Over 25 years experience building fast growth business in the US with global operations. Numerous board assignments on both public and private boards. Significant experience in investor relations and board fiduciary responsibilities and vigilance. Experienced in guiding start-ups and growing companies domestically and globally. Has managed corporate investor relations and capital raises. Previously was President of MusclePharm a public sports nutrition company that grew from $67M to a $200M run rate during his tenure. Also was Senior Vice President at Arbonne, a multi level marketing company that grew from $100M to a billion dollar run rate during his tenure. Lastly was a Senior Vice President and Operating Officer at Office Depot. Started with the company when it was starting up and left when the company was at $8 billion dollars.
Formerly the Medical Director of Roche Australia and Member of Global Leadership Team, Clinical for Roche/Genentech where, over a 30 year career, he was involved in all product lifecycle phases from phase 1 to 4 including clinical development, regulatory, PBS listing and medical affairs for more than 40 new pharmaceutical products (gross revenues of US$100B), including Pegasus for Hep B and C, MabThera for oncology, Naproxen for pain relief and Midazolam for anaesthetic induction and sedation for short periods.
Ms Glover has over 20 years’ experience in private practice providing legal, corporate governance and company secretarial advice to a range of companies including ASX listed companies, private and not-for-profit organisations
Mr Forbes is Chartered Accountant (CA) with over 20 years’ experience with private and ASX listed public companies. Ian has experience with mature and developing organisations nationally and internationally. Mr Forbes graduated from the University of New England and became a CA in 1998 then worked in business services at BDO and PWC. Having worked in industry with small start-up companies through to large U.S. and Japanese multinational companies, Ian has broad expertise in all facets of financial management.
ABN 16 657 241 533